Aytu BioPharma and Lannett Company mutually terminated the Metadate Agreement on June 23, 2026. The agreement, originally signed in May 2022 and amended twice, is now terminated in its entirety, subject to specific survival clauses. Aytu retains the right to sell and distribute existing inventory of Metadate CD at its discretion. The company is obligated to continue providing royalty reports and payments until all existing inventory is sold. Metadate CD generated $49,000 in net revenue for the quarter ended March 31, 2026.